Emergent BioSolutions closes acquisition of smallpox drug from Chimerix

Gaithersburg’s Emergent BioSolutions Inc. (NYSE: EBS) has completed its acquisition of a smallpox drug, four months after striking the deal — and paving another path for the local company to bolster the national stockpile. Emergent said this week it closed its agreement with Durham, North Carolina’s Chimerix Inc. (NASDAQ: CMRX) for exclusive worldwide rights to Tembexa, the first treatment for smallpox greenlit by the Food and Drug Administration.